A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

计划入组 24 人 · 首次发布于 2025 年 6 月 26 日

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

计划入组 80 人 · 首次发布于 2026 年 7 月 2 日

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

计划入组 24 人 · 首次发布于 2025 年 6 月 26 日

ENTR-601-44

ENTR-601-45

ENTR-601-50

浙江章光101有限公司

北京章光101药业有限公司

北京章光101科技股份有限公司

Entrada Therapeutics Advances DMD Treatment: UK MHRA Approves Phase I/II Trial for Novel Exon-Skipping Therapy

Entrada Therapeutics Advances RNA-Based Pipeline with First Ocular Candidate for Usher Syndrome

Terns Pharmaceuticals Advances CML Drug TERN-701 and Obesity Treatment TERN-601 in Clinical Trials